| Characteristic | United States | Europe* | Japan | Pharmerging** | Rest of world |
|---|---|---|---|---|---|
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
Download
Source
Sources
Release date
June 2026
More information
Region
Worldwide
Survey time period
2004 to 2024
Supplementary notes
EFPIA stands for European Federation of Pharmaceutical Industries and Associations. This statistic was assembled from several editions of this EFPIA report.
* Europe includes only top 5 European countries: Germany, UK, France, Spain, and Italy.
** Pharmerging comprises 21 countries ranked by IQVIA as high-growth
pharmaceutical markets. Among others, they include Brazil, China, India, and Russia.
Citation formats
